Stay updated on Nivolumab in Type B3 Thymoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Type B3 Thymoma Clinical Trial page.

Latest updates to the Nivolumab in Type B3 Thymoma Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed study information regarding the phase II Nivothym study and its inclusion criteria, while adding new identifiers and collaborators related to the study.SummaryDifference44%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check87 days agoChange DetectedThe page now indicates that some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. Additionally, the status of a service has been updated to 'Verified 2023-02' by the European Organisation for Research and Treatment of Cancer, while the previous status 'Active, not recruiting' has been removed.SummaryDifference2%
Stay in the know with updates to Nivolumab in Type B3 Thymoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Type B3 Thymoma Clinical Trial page.